MedTrace Logo

Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients

NCT03514875 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-08-15

No results posted yet for this study

Summary

Neurodegenerative diseases such as Mild Cognitive Impairment, Alzheimer's, and dementia affect millions of Americans. Although these diseases are heavily researched, there is very little research examining the impact of attenuated carotid artery endothelial function and cerebrovascular blood flow on cognitive function. This is surprising, as cerebrovascular oxygenation has been shown to be strongly associated with reduced cognitive function and the pathogenesis of neurodegenerative diseases. For example, hypertension, diabetes, and high cholesterol have been shown to increase the risk of Alzheimers related dementia. Therefore, the purpose of this proposed study will be to examine the effects of MitoQ supplementation on carotid artery vasodilatory function and cerebrovascular blood flow in those suffering from Mild Cognitive Impairment (MCI). MitoQ is a mitochondria-targeting antioxidant that can improve nitric oxide production in the blood vessel, which should improve endothelial function, and thus cerebrovascular blood flow.

Conditions

Interventions

DIETARY_SUPPLEMENT

MitoQ

MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation

DIETARY_SUPPLEMENT

Placebo

A placebo will be used in a double blinded, randomized, cross-over design

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Song-young Park, PhD · University of Nebraska

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-11
Primary Completion
2022-07-18
Completion
2022-07-18

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03514875 on ClinicalTrials.gov